Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, Brazil
Autor(a) principal: | |
---|---|
Data de Publicação: | 2009 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Revista Brasileira de Medicina de Família e Comunidade (Online) |
Texto Completo: | https://www.rbmfc.org.br/rbmfc/article/view/420 |
Resumo: | Objectives: know the mqgniulde of the problem of Hepatitis A in Parana, Brazil, and assess the cost-benefit ratio of vaccination. Materials and methods: the study is descriptive and pharmacoeconomical. To assess the magnitude of the problem, data were collected on cases of hepatitis A from the Information System of Worsening Notification (SINAN), Information System in Mortality (SIM) and Hospitalization Authorization (AIH) of the State Secretariat of I Health of Paraná referring to the period from 2000 to 2003. The probability of one tenth of children acquiring Hepatitis A during their lifetime was estimated along with the costs of the treatments. These expenses were compared with the cost of vaccination. Results: there were 14,682 notices of which 12,102 (82.4%) occurred in children under 15 years of age. The incidence on the population was 37.5/100000. There were 20 deaths, being 7 due to liver failure. Costs with the disease were truly high.. The investment in children vaccination, with two doses (10 USD / dose), was also estimated. A positive cost-benefit relation of the vaccination was observed. For each dollar invested in vaccination, US$ 2.26 are saved on the treatment. Conclusions: the results confirm the positive cost-benefit relation of the vaccine. Since this is the first pharmacoeconomic study on vaccination against hepatitis A in our environment, the need for more in-depth and encompassing studies is highlighted with the goal of complementing a few aspects not explored yet. |
id |
SBMFC-1_56940471c2e4cb71a14696dceff6a44d |
---|---|
oai_identifier_str |
oai:ojs.rbmfc.org.br:article/420 |
network_acronym_str |
SBMFC-1 |
network_name_str |
Revista Brasileira de Medicina de Família e Comunidade (Online) |
repository_id_str |
|
spelling |
Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, BrazilHepatite A: avaliação do custo-beneficio da prevenção pela vacina - Paraná, BrasilHepatitis AEpidemiologyVaccines Against Hepatitis ACost-Benefit AnalysisHepatite AEpidemiologiaVacinas Contra Hepatite AAnálise Custo-BeneficioObjectives: know the mqgniulde of the problem of Hepatitis A in Parana, Brazil, and assess the cost-benefit ratio of vaccination. Materials and methods: the study is descriptive and pharmacoeconomical. To assess the magnitude of the problem, data were collected on cases of hepatitis A from the Information System of Worsening Notification (SINAN), Information System in Mortality (SIM) and Hospitalization Authorization (AIH) of the State Secretariat of I Health of Paraná referring to the period from 2000 to 2003. The probability of one tenth of children acquiring Hepatitis A during their lifetime was estimated along with the costs of the treatments. These expenses were compared with the cost of vaccination. Results: there were 14,682 notices of which 12,102 (82.4%) occurred in children under 15 years of age. The incidence on the population was 37.5/100000. There were 20 deaths, being 7 due to liver failure. Costs with the disease were truly high.. The investment in children vaccination, with two doses (10 USD / dose), was also estimated. A positive cost-benefit relation of the vaccination was observed. For each dollar invested in vaccination, US$ 2.26 are saved on the treatment. Conclusions: the results confirm the positive cost-benefit relation of the vaccine. Since this is the first pharmacoeconomic study on vaccination against hepatitis A in our environment, the need for more in-depth and encompassing studies is highlighted with the goal of complementing a few aspects not explored yet.Objetivos: conhecer a magnitude do problema da Hepatite A no Parana. , Brasil, e avaliar custo-beneficio davacinação. Materiais e métodos: o estudo é descritivo e de farmacoeconomia. Para avaliar a magnitude do problema,foram coletados dados sobre os casos de hepatite A do Sistema de Informação de Agravos de Notificação, (SIN AN),Sistema de Informação em Mortalidade (SIM) e Autorização de Internação Hospitalar (A114) da Secretaria de Estado daSaúde do Paraná ao período de 2000 a 2003. Foi estimada a probabilidade de uma coorte de crianças adquirirHepatite A durante a vida e os custos dos tratamentos. Esses gastos foram comparados corn o custo da vacinação.Resultados: foram 14.682 notificações das quais 12.102 (82,4%) ocorreram em menores de 15 anos. A incidência napopulação foi de 37,5/100000. Ocorreram 20 óbitos, sendo sete por insuficiência hepática. O custo com a doença foicomprovaciamente alto. 0 investimento para a vacinação de crianças, com duas doses (10 LTSD/dose), também foiestimado. Observou-se uma relação custo-beneficio positiva da vacinação. Para cada dólar investido na vacinação, 2,26LTSD sic) economizados no tratamento. Conclusões: os resultados confirmam a relação custo-beneficio positiva davacina. Sendo esse o primeiro estudo farmacoeconOmico sobre a vacinação contra hepatite A em nosso meio, apontasepara a necessidade de pesquisas mais aprofundadas e abrangentes, com o intuito de complementar alguns aspectosainda não explorados.Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC)2009-11-17info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos Originais; Original Articlesapplication/pdfhttps://www.rbmfc.org.br/rbmfc/article/view/42010.5712/rbmfc4(16)420Revista Brasileira de Medicina de Família e Comunidade; Vol. 4 No. 16 (2009); 281-288Revista Brasileira de Medicina de Família e Comunidade; Vol. 4 Núm. 16 (2009); 281-288Revista Brasileira de Medicina de Família e Comunidade; v. 4 n. 16 (2009); 281-2882179-79941809-5909reponame:Revista Brasileira de Medicina de Família e Comunidade (Online)instname:Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC)instacron:SBMFCporhttps://www.rbmfc.org.br/rbmfc/article/view/420/324Copyright (c) 2009 Mariana Ribas Zahdi, Ivan Maluf Junior, Eliane Mara Cesario Pereira Malufinfo:eu-repo/semantics/openAccessZahdi, Mariana RibasMaluf Junior, IvanMaluf, Eliane Mara Cesario Pereira2020-05-21T20:22:21Zoai:ojs.rbmfc.org.br:article/420Revistahttp://www.rbmfc.org.br/index.php/rbmfchttps://www.rbmfc.org.br/rbmfc/oai||david@sbmfc.org.br2179-79941809-5909opendoar:2020-05-21T20:22:21Revista Brasileira de Medicina de Família e Comunidade (Online) - Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC)false |
dc.title.none.fl_str_mv |
Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, Brazil Hepatite A: avaliação do custo-beneficio da prevenção pela vacina - Paraná, Brasil |
title |
Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, Brazil |
spellingShingle |
Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, Brazil Zahdi, Mariana Ribas Hepatitis A Epidemiology Vaccines Against Hepatitis A Cost-Benefit Analysis Hepatite A Epidemiologia Vacinas Contra Hepatite A Análise Custo-Beneficio |
title_short |
Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, Brazil |
title_full |
Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, Brazil |
title_fullStr |
Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, Brazil |
title_full_unstemmed |
Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, Brazil |
title_sort |
Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, Brazil |
author |
Zahdi, Mariana Ribas |
author_facet |
Zahdi, Mariana Ribas Maluf Junior, Ivan Maluf, Eliane Mara Cesario Pereira |
author_role |
author |
author2 |
Maluf Junior, Ivan Maluf, Eliane Mara Cesario Pereira |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Zahdi, Mariana Ribas Maluf Junior, Ivan Maluf, Eliane Mara Cesario Pereira |
dc.subject.por.fl_str_mv |
Hepatitis A Epidemiology Vaccines Against Hepatitis A Cost-Benefit Analysis Hepatite A Epidemiologia Vacinas Contra Hepatite A Análise Custo-Beneficio |
topic |
Hepatitis A Epidemiology Vaccines Against Hepatitis A Cost-Benefit Analysis Hepatite A Epidemiologia Vacinas Contra Hepatite A Análise Custo-Beneficio |
description |
Objectives: know the mqgniulde of the problem of Hepatitis A in Parana, Brazil, and assess the cost-benefit ratio of vaccination. Materials and methods: the study is descriptive and pharmacoeconomical. To assess the magnitude of the problem, data were collected on cases of hepatitis A from the Information System of Worsening Notification (SINAN), Information System in Mortality (SIM) and Hospitalization Authorization (AIH) of the State Secretariat of I Health of Paraná referring to the period from 2000 to 2003. The probability of one tenth of children acquiring Hepatitis A during their lifetime was estimated along with the costs of the treatments. These expenses were compared with the cost of vaccination. Results: there were 14,682 notices of which 12,102 (82.4%) occurred in children under 15 years of age. The incidence on the population was 37.5/100000. There were 20 deaths, being 7 due to liver failure. Costs with the disease were truly high.. The investment in children vaccination, with two doses (10 USD / dose), was also estimated. A positive cost-benefit relation of the vaccination was observed. For each dollar invested in vaccination, US$ 2.26 are saved on the treatment. Conclusions: the results confirm the positive cost-benefit relation of the vaccine. Since this is the first pharmacoeconomic study on vaccination against hepatitis A in our environment, the need for more in-depth and encompassing studies is highlighted with the goal of complementing a few aspects not explored yet. |
publishDate |
2009 |
dc.date.none.fl_str_mv |
2009-11-17 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Artigos Originais; Original Articles |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.rbmfc.org.br/rbmfc/article/view/420 10.5712/rbmfc4(16)420 |
url |
https://www.rbmfc.org.br/rbmfc/article/view/420 |
identifier_str_mv |
10.5712/rbmfc4(16)420 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://www.rbmfc.org.br/rbmfc/article/view/420/324 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2009 Mariana Ribas Zahdi, Ivan Maluf Junior, Eliane Mara Cesario Pereira Maluf info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2009 Mariana Ribas Zahdi, Ivan Maluf Junior, Eliane Mara Cesario Pereira Maluf |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC) |
publisher.none.fl_str_mv |
Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC) |
dc.source.none.fl_str_mv |
Revista Brasileira de Medicina de Família e Comunidade; Vol. 4 No. 16 (2009); 281-288 Revista Brasileira de Medicina de Família e Comunidade; Vol. 4 Núm. 16 (2009); 281-288 Revista Brasileira de Medicina de Família e Comunidade; v. 4 n. 16 (2009); 281-288 2179-7994 1809-5909 reponame:Revista Brasileira de Medicina de Família e Comunidade (Online) instname:Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC) instacron:SBMFC |
instname_str |
Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC) |
instacron_str |
SBMFC |
institution |
SBMFC |
reponame_str |
Revista Brasileira de Medicina de Família e Comunidade (Online) |
collection |
Revista Brasileira de Medicina de Família e Comunidade (Online) |
repository.name.fl_str_mv |
Revista Brasileira de Medicina de Família e Comunidade (Online) - Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC) |
repository.mail.fl_str_mv |
||david@sbmfc.org.br |
_version_ |
1752122105889030144 |